Stay updated on Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Added a government funding–related notice about possible delays in updating information. Updated the page revision from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T10:18:10.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The page now includes a 'Show glossary' option, adds 'No FEAR Act Data' and 'Revision: v3.4.0' in the footer, and updates the label to 'Last Update Submitted that Met QC Criteria'.
    Difference
    0.2%
    Check dated 2026-01-28T04:59:04.000Z thumbnail image
  3. Check
    21 days ago
    No Change Detected
  4. Check
    28 days ago
    Change Detected
    Summary
    Revision v3.3.4 added and revision v3.3.3 removed; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T02:22:59.000Z thumbnail image
  5. Check
    50 days ago
    Change Detected
    Summary
    A new study location in Illinois was added and the footer revision updated to v3.3.3; the HHS Vulnerability Disclosure entry was removed.
    Difference
    0.2%
    Check dated 2025-12-23T17:21:09.000Z thumbnail image
  6. Check
    79 days ago
    Change Detected
    Summary
    Publication notes now state that PubMed publications are auto-filled, and the old PubMed wording was removed; the page revision has been updated to v3.3.2, replacing the previous v3.2.0.
    Difference
    0.1%
    Check dated 2025-11-24T18:49:14.000Z thumbnail image
  7. Check
    86 days ago
    Change Detected
    Summary
    The NIH operating-status notice has been removed from the page. All study details, eligibility criteria, and related content appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-17T17:59:48.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page.